As reported in our August 7, 2024, blog item, the U.S. Food and Drug Administration (FDA) announced on August 1, 2024, that it will hold a public meeting on September 25, 2024, on the development of ...
On March 15, 2024, FDA published a white paper titled “Artificial Intelligence & Medical Products: How CBER, CDER, CDRH, and OCP are Working Together” (the AI White Paper) on the use of artificial ...
With states like California, Illinois, and New York questioning the safety of certain food additives and some other chemicals used in food, the public is wondering if a food is safe to eat if it ...
The US Food and Drug Administration (FDA) has released a discussion paper on using artificial intelligence and machine learning in drug and biological product development. FDA’s discussion paper ...
Please provide your email address to receive an email when new articles are posted on . Speakers at a congressional briefing highlighted safety concerns around counterfeit GLP-1 drugs. A white paper ...
Rapid scientific advances are accelerating the development of medical innovations, from personalized treatments to curative gene therapies and advanced diagnostic tools. But significant policy and ...
The US Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER) this week released a white paper aimed at encouraging the use of selective safety data collection (SSDC).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results